The Endogenous Incretin Edge: Leveraging Bitter Botanicals for Gut-Brain Signaling

While synthetic GLP-1 receptor agonists have brought the gut brain axis to the forefront of metabolic care, pharmacotherapy can bypass natural physiology and broader incretin networks. Bitter botanicals offer a targeted alternative: activating extra oral bitter taste receptors (TAS2Rs) throughout the gastrointestinal tract to stimulate endogenous GLP-2 PYY, and CCK secretion. This session explores the clinical application and emerging evidence for key metabolic phytocompounds.

Attendees will learn practical, evidence informed strategies to leverage bitter botanicals to optimize gut brain signaling, enhance physiological satiety, and deliver sustainable metabolic outcomes.